ReviewOncogene2010
Harnessing the immune response to treat cancer.
Review in Oncogene, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- An immune-active tumor microenvironment favors clinical response to ipilimumab.Cancer immunology, immunotherapy : CII · 2012Trial
- Copper homeostasis and copper-induced cell death in tumor immunity: implications for therapeutic strategies in cancer immunotherapy.Biomarker research · 2024Review
- Sentinel Lymph Node in Non-Small Cell Lung Cancer: Assessment of Feasibility and Safety by Near-Infrared Fluorescence Imaging and Clinical Consequences.Journal of personalized medicine · 2022Article
- Potential Application of Exosomes in Vaccine Development and Delivery.Pharmaceutical research · 2022Review
- Chaperone-assisted E3 ligase CHIP: A double agent in cancer.Genes & diseases · 2022Review
- Exosome-related Methods and Potential Use as Vaccines.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used.Cancer immunology, immunotherapy : CII · 2021Article
- Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy.Frontiers in oncology · 2021Review
- Role of the Cyclooxygenase Pathway in the Association of Obstructive Sleep Apnea and Cancer.Journal of clinical medicine · 2020Review
- Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade.Frontiers in immunology · 2020Review
- CD8Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- Urothelial bladder cancer may suppress perforin expression in CD8+ T cells by an ICAM-1/TGFβ2 mediated pathway.PloS one · 2018Article
- Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.Oncotarget · 2017Article
- Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols.JCI insight · 2017Article
- Elevated neutrophil-to-lymphocyte ratio is an independent poor prognostic factor in patients with intrahepatic cholangiocarcinoma.Oncotarget · 2016Article
- The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.The oncologist · 2016Review
- TLR4-mediated immunomodulatory properties of the bacterial metalloprotease arazyme in preclinical tumor models.Oncoimmunology · 2016Article
- IFN-α potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer.Oncotarget · 2016Article
- C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation.Nature communications · 2016Article
- CpG expedites regression of local and systemic tumors when combined with activatable nanodelivery.Journal of controlled release : official journal of the Controlled Release Society · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is well established that the immune system has the capacity to attack malignant cells. During malignant transformation cells acquire numerous molecular and biochemical changes that render them potentially vulnerable to immune cells. Yet it is self-evident that a growing tumour has managed to evade these host defence mechanisms. The exact ways in which the immune system interacts with tumour cells and how cancers are able to escape immunological eradication have only recently started to be fully elucidated. Understanding the relationship between the tumour and the anti-tumour immune response and how this can be altered with conventional treatments and immune-targeted therapies is crucial to developing new treatments for patients with cancer. In this review, focusing on the anti-tumour T-cell response, we summarize our understanding of how tumours, cancer treatments and the immune system interact, how tumours evade the immune response and how this process could be manipulated for the benefit of patients with cancer.
Indexed as
Identifiers
20856204What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.